Revolution Medicines stock surges as pancreatic cancer drug doubles survival in phase 3 trial

Apr 13, 2026, 3:51:20 PM UTC(1 day ago)

Impact: Medium

Affected Assets

The phase 3 RASolute 302 trial showed daraxonrasib improved median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy
Revolution Medicines reported a hazard ratio of 0.40 with high statistical significance for patients with previously treated metastatic pancreatic ductal adenocarcinoma
Shares of RVMD jumped as much as 40 percent in premarket trading following the announcement of the unprecedented survival benefit
The company plans to submit a New Drug Application to the FDA using a National Priority Voucher and will present full data at the 2026 ASCO meeting
Analysts from RBC Capital Markets estimate the total market opportunity for the oral once-daily pill could exceed 10 billion dollars

$RVMD soars by more than 35% on positive phase 3 trial results for its metastatic pancreatic cancer drug, daraxonrasib. 📈 https://t.co/KoEozLA4xx